Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06541327
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-30
Brief Title:
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to collect clinical data from adult patients with relapsed or refractory non-Hodgkins lymphoma rr NHL receiving cellular immunotherapy to establish a large database of cellular immunotherapy for Chinese patients
Detailed Description:
This study aims to collect efficacy and safety data from adult patients with rr NHL who received cellular immunotherapy between January 2017 and December 2040 Study investigators will determine the most appropriate diagnostic and treatment plans for patients based on clinical practice without any intervention due to the existence of this study No grouping will be conducted and subgroup analyses will be performed based on the collected data
Data collection process
Clinical data will be collected from patients before cellular immunotherapy before immune cell infusion on the day of infusion and at the last visit or follow-up within 24 months post-infusion This includes collecting efficacy data adverse events related to cellular immunotherapy and survival data Additionally any new tumors pathological findings and other relevant laboratory or auxiliary examination data will be collected
Data collection process
Clinical data will be collected from patients before cellular immunotherapy before immune cell infusion on the day of infusion and at the last visit or follow-up within 24 months post-infusion This includes collecting efficacy data adverse events related to cellular immunotherapy and survival data Additionally any new tumors pathological findings and other relevant laboratory or auxiliary examination data will be collected
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None